Summary Fifty-one samples of non-malignant tissue from four mastectomies were analysed to assess oestrogen receptor (ER) and epidermal growth factor receptor (EGFR) status across the cancerous breast. No significant relationship was found between the presence of EGFR and ER. Eighty-four per cent of these samples were EGFR positive and 29% expressed both receptor types. EGFR and ER expression was not affected by histological sub-group. In contrast, analysis of 44 primary cancers showed, in agreement with the literature, a significant inverse relationship between the presence of ER and EGFR (Fisher's exact test P<0.002). The difference between malignant and non-malignant tissue appeared to result from the prevalence of co-expression of EGFR and ER in the non-malignant specimens. This suggests different regulation of receptor expression in malignant and non-malignant tissue.
As a consequence of the increasing awareness of the role of peptide growth factors in cellular growth, differentiation and proliferation in normal tissue (Rowe & Friesen, 1984) and in malignancy (Sporn & Roberts, 1985; Anonymous, 1986; Lippman et al., 1986 Lippman et al., , 1987 , attention is being focused on the expression of their receptors in breast cancer. The receptor for epidermal growth factor (EGF) is of particular interest because of experimental evidence linking EGF with carcinogenesis (Stoschek & Lloyd, 1986) .
In the past 4 years a great deal of evidence has been obtained which suggests that an inverse relationship exists between epidermal growth factor receptor (EGFR) and oestrogen receptor (ER) expression in primary breast carcinomas in that co-expression of these two receptor types is rare, and most tumours are either ER + ve or EGFR + ve (Perez et al., 1984; Sainsbury et al., 1985a Sainsbury et al., , b, 1987 Sainsbury et al., , 1988 Skoog et al., 1986; Davidson et al., 1987; Wyss et al., 1987; Macias et al., 1987; Nicholson et al., 1988a Nicholson et al., , 1989 Pekonen et al., 1988; Travers et al., 1988; Cappelletti et al., 1988; Wrba et al., 1988; Delarue et al., 1988) . It has also been suggested that the detection of EGFR in a primary breast tumour indicates a poor prognosis (Sainsbury et al., 1987; Nicholson et al., 1989) . As the expression of EGFR is not limited to malignant breast cells but has also been found in normal breast tissue adjacent to primary tumours (Ozawa et al., 1988) and in the normal breast cell line, HBL-100 (Fitzpatrick et al., 1984) , and furthermore since cultured cells from benign breast fibroadenomas have been shown to respond to EGF in vitro (Stokes et al., 1976) used as positive controls. Intra-assay variation was less than 5% and inter-assay variation was 9%. The detection limit for the assay (value significantly different from zero) was 3 fmol mg ' protein and specific binding was invariably greater than 25% of total binding.
Steroid hormone receptor radioligand binding assays
The single-saturating dose assay (King et al., 1979; Puddefoot et al., 1987) was used to measure soluble oestrogen receptors. Briefly, this involved incubation of aliquots of cytosol in the presence of 17 nM tritiated 17-beta oestradiol (sp.act.llCi mmol-') for 18 h at 4°C, without or with a 100-fold excess of diethylstilboestrol, to determine total and non-specific binding, from which a value for specific (receptor) binding was obtained. Bound radioactivity was separated by the dextran-coated charcoal method and counted by liquid scintillation spectrophotometer. The detection limit for this assay was 5 fmol mg-' protein.
A single-saturating dose assay also was used to determine progesterone receptor concentrations. (Table I) . Similarly, no significant differences were found between the relative proportions of each receptor phenotype in a given sub-group (Table II) . Comparison of tissue yields between non-malignant tissue groups and the tumour group (Table III) indicates that the latter shows relatively higher protein yields for both membrane and cytosolic fractions. 
Discussion
Our data represent the first systematic study of the relationship between EGFR and ER in the cancerous breast after excision of the primary cancer. EGFR is present in all types of non-malignant tissue although its level of expression may be relatively low compared with the top range previously reported in primary breast tumours. Furthermore, the results from the series of tumours analysed in this study agree with previous work in demonstrating the absence of EGFR and ER co-expression, and it is therefore extremely significant to find that in the non-malignant group the two receptor types
were found to co-exist in a significant proportion of specimens analysed, irrespective of histological sub-group. This finding is the more remarkable in view of the highly heterogeneous nature and the frequently low cellularity of nonmalignant breast tissue (Table III) . The results suggest that the inverse relationship between ER and EGFR which is found in tumours may reflect an abnormal regulatory state confined to the tumour itself. Travers et al. (1988) (Stoschek & Lloyd, 1986) . It might be argued that if TGF-alpha is produced in tumours in sufficiently high concentration (Dickson & Lippmann, 1986; Bates et al., 1988 ) EGFR sites may be saturated and thus be undetectable by radioligand binding assay, whereas in normal tissue low levels of EGFR might be detectable. This argument would conflict with the evidence of Travers et al. (1988) , who showed that mRNA for ER and EGFR were not found to co-exist to any significant extent in primary breast carcinomas. It is well established that in addition to stimulating EGFR mRNA synthesis, EGF or TGF-alpha can cause 'down-regulation' of EGFR by receptor internalisation and degradation (Carpenter, 1987; Schlessinger, 1988 (Ro et al., 1988) or high transcription rates (Davidson et al., 1987) which are not subject to normal regulatory mechanisms.
An alternative explanation for the differences between nonmalignant tissue and primary breast cancers might be that the tumours represent clonal selection of cells which express only one or other of these receptor types. Wrba et al. (1988) have suggested that the inverse relationship between EGFR and ER status may indicate the existence of two different sub-populations on the basis of differentiation and growth control. One group may represent those tumours which are primarily regulated by EGF and EGF-related molecules. The other group may consist of tumours predominantly responsive to steroid hormones. Meanwhile, as we have shown in non-malignant tissue both EGFR and ER can more often be detected in the same tissue specimen implying that normally both receptor types are expressed.
We conclude therefore, from our data on non-malignant tissue, that in the normal breast both ER and EGFR co-exist to maintain regulated cell growth, and that this system becomes uncoupled during malignant transformation.
